Ticagrelor vs Clopidogrel in Acute Coronary Syndrome

Primary Findings and Clinical Implications

Among patients managed without a planned invasive strategy, ticagrelor showed a 15% reduction in the primary endpoint, consistent with the overall trial results 1, 2
The American College of Cardiology/American Heart Association guidelines recommend ticagrelor over clopidogrel for ACS patients due to its superior reduction in cardiovascular events 3, 1
For patients requiring CABG surgery, ticagrelor has a shorter recommended interruption period compared to clopidogrel 3, 2
Clopidogrel remains an effective alternative P2Y12 inhibitor for patients with high bleeding risk or contraindications to ticagrelor 1, 2

Significant interpatient variability exists in pharmacodynamic response to clopidogrel, which is not seen to the same extent with ticagrelor 2
Dyspnea occurs in up to 15% of patients taking ticagrelor 4
Ticagrelor does not require hepatic conversion to an active metabolite, allowing for more rapid onset of action compared to clopidogrel 4